How can we facilitate the delivery of advanced therapies to patients? by Mahalatchimy, Aurélie
	
	
www.ebmt.org #EBMT18 
How can we facilitate the delivery of advanced 
therapies to patients? 
Aurélie Mahalatchimy, CNRS permanent researcher in health law 
UMR 7318 DICE CERIC, CNRS-Aix-Marseille Université-Université de Pau et des Pays de 
l’Adour-Université de Toulon et du Var, Aix-en-Provence, FRANCE 
 No conflict of interest 
Lisbon, 19/03/2018 
	
	
2 
•  Focus on Advanced Therapy Medicinal Products (ATMPs) as defined by 
Regulation (EC) n°1394/2007 
–  Gene therapy 
–  Tissue engineering and Cell therapy from human and xenogeneic cells 
–  Cells and tissues associated with medical devices (Combined) 
 
 
Use of human body elements (genes, cells, tissues) for therapeutic purposes 
Transformation into medicinal products, often ATMPs 
 
 
Strict and specific legal frameworks for ATMPs within regenerative medicine 
Advanced Therapies? 
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•  Cases of market failures and consequences 
•  Clinical delivery Issues 
•  Solution 1: The UK Advanced Therapies Treatment Centres 
•  Solution 2: Complementary activities 
•  Solution 3: New approach from Social and Human Sciences 
Outline 
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•  Clinical adoption has been recognized as a main challenge in the field of 
advanced therapies 
–  From bench to bedside approach, Translational medicine 
–  Product’s “life cycle” 
–  “One of the greatest changes to the delivery of medicine in recent 
times” (Medicine Manufacturing Industry Partnership, Advanced Therapies Manufacturing Action Plan: Retaining 
and Attracting Advanced Therapies Manufacture in the UK, 2017) 
–  Different aspects between existing healthcare delivery mechanisms for drug 
and devices and those required for tissue, cell or gene-based products 
Consequences of market failures 
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•  Clinical complexity: Highly sensitive (living) tissues and cells, complexity 
of the processes 
•  Need for specific skills and training  
•  Need for new logistical arrangements  
–  Manufacturing: on site, expensive bioprocessing equipment… 
–  Transport: often short shelf life 
–  Storage: specific equipment 
•  Funding of products: high cost, risk-sharing agreements and data 
gathering 
•  Limits of healthcare systems: limited health budget and resources, 
already busy 
•  Managing patients’ hopes and hypes 
Clinical delivery issues 
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•  2015 and 2017: Thank tanks’ proposals of establishment of specialist cell 
and gene therapy delivery centres in the UK 
•  2017: UK Government devoted £30 millions for a network of Advanced 
therapies treatment centres in the UK  
•  February 2018: project started under the coordination of the Cell and 
Gene Therapy Catapult.  
It involves 3 Consortia that received funding 
–  Midlands and Wales Advanced Therapy Treatment Centre 
–  Northern Alliance Advanced Therapies Treatment Centre 
–  A Coordinated strategy to scale-up advanced therapies for patients in 
Manchester  
The UK Advanced Therapies Treatment Centres 
The EBMT Legal and Regulatory Affairs Committee special, 19/03/2018- Lisbon-Portugal 
Midlands and Wales Centre Northern Alliance Centre Manchester Coordinated 
strategy 
National Institute for Health 
Research Birmingham 
Biomedical Research Centre 
Nottingham Uni Hosp. NHS Trust 
Velindre NHS Trust 
 
NHS Blood and Transplant 
 
 
 
Asymptote Ltd 
World Courier Logistics Ltd 
Thermo Electron Ltd 
Cell Medica Ltd 
Miltenyi Biotec Ltd 
Trakcel Ltd 
 
Cellular Therapeutics Ltd 
 
Rexgenero Ltd 
Orbsen Therapeutics UK Ltd 
The Newcastle upon Tyne Hospitals NHS Foundation Trust 
NHS Lothian 
NHS Greater Glasgow and Clyde 
Leeds Teaching Hospital NHS Trust 
Academic Health Science Network for the North East and 
North Cumbria 
NHS Blood and Transplant 
Scottish National Blood Transfusion Service 
Edinburgh University 
Newcastle University 
Asymptote Ltd (part of GE Healthcare) 
World Courier Logistics Ltd 
Thermo Electron Ltd 
Cell Medica Limited 
Miltenyi Biotec Limited 
TrakCel Limited 
Datatrial Ltd 
 
Chiesi Ltd 
Autolus Limited 
Roslin Cell Therapies Limited 
Alcyomics Limited 
The Christie NHS Foundation 
Trust 
Manchester University NHS Trust 
 
Christie Pathology Partnership 
 
 
 
University of Manchester  
 
Asymptote Ltd 
 
 
 
 
 
Datatrial Ltd 
Celluar Therapeutics Limited 
Chaucer Group Limited 
AstraZeneca plc 
Agenus UK Ltd 
Aptus Clinical Limited 
Formedix Limited 
	
	
9 
•  How?  
–  Partnerships between NHS (patient access, clinical and tissue and blood 
expertise) and industry (investment and manufacturing expertise) 
–  Consolidation of resources around these centres and coordination 
•  Where? 
–  Sites already pioneering the development and clinical trials of ATMPs, with 
will to improve expertise in manufacturing and delivery  
•  Why? 
–  To develop coordinated systems with the necessary skills for at-scale clinical 
delivery 
–  To facilitate the establishments of validated standards of quality and safety of 
ATMPs. 
 
The UK Advanced Therapies Treatment Centres 
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•  A specific role for haematological services  
–  Similarities shared between many ATMPs and existing conventional 
haematological treatments  
o  Haematologists departments well placed for ATMPs development but needs to  
accommodate with new issues and requirements (see Lowdell & Thomas 2017) 
•  New manufacturing centres, examples: 
–  Cell and Gene Therapy Catapult large GMP manufacturing centre in 
Stevenage in the UK: £55 millions investment, 100m2 of clean room space 
–  YpoSkesi in France: 121 millions euros, 6000m2 to be expanded 
•  Enhanced coordination between gatekeeping institutions (regulatory 
agencies and reimbursement bodies) in the UK 
•  Early contact with regulators favoured at EU and UK levels 
Complementary activities 
The EBMT Legal and Regulatory Affairs Committee special, 19/03/2018- Lisbon-Portugal 
	
	
11 
•  The REGenableMED project (PI: A. Webster, University of York) 
“Regenerative	medicine	and	its	development	and	implementation:	an	analysis	of	
emergent	value	systems	and	health	service	readiness”	
Universities	of	York	(SATSU);	Sussex	(Centre	for	Global	Health	Policy);	Edinburgh	
(INNOGEN);	Birmingham	(national	Horizon	Scanning	Centre).	
May	2014-	July	2017	
Sociology/Science	&	Technology	Studies;	business	modelling;	law	&	regulation;	
horizon	scanning	&	scenario	methods	
The support of social and human 
sciences 
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•  In parallel with Technology Level Readiness (TRL), Institutional 
readiness (IR) (See Webster 2017) 
–  TRL focus on innovation as “working”, current approach of acceleration for 
the market 
–  IR: “the capacity and willingness of key pre-existing organisations and inter-
organisational structures to adopt, respond to and utilise novel technologies” 
o  Need for innovation to be “workable”, i.e. to make sense in their context of 
application: clinical delivery, administration to the patient within the clinic. 
o  “Responsible acceleration” 
The REGenableMED results 
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•  But also Workability through  
–  Practices (See Isasi et al 2017) 
–  Public private partnerships and re-negociation of science in context (See 
Addison 2017) 
–  More coordination between various actors, and particular roles of 
intermediary agencies (such as UK Gene and Cell Therapy Catapult; See 
Gardner and Webster 2017) 
•  To address clinical delivery issues, especially 
–  Diversity of ATMPs: to take into account the context 
–  Unclear requirements due to early stages therapies 
The support of social and human 
sciences 
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Reports 
•  Regenerative Medicine Expert Group: Building on our own Potential: A UK Pathway for Regenerative Medicine (2015). Available at 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/415919/build-on-potential.pdf   
•  Medicine Manufacturing Industry Partnership, Advanced Therapies Manufacturing Action Plan: Retaining and Attracting Advanced Therapies 
Manufacture in the UK, 2017: http://www.abpi.org.uk/our-work/mmip/Documents/Advanced-Therapies-Manufacturing-Taskforce-report.pdf 
•  Advanced Therapies Manufacturing Taskforce report, November 2017, http://www.bioindustry.org   
•  REGenableMED project, Policy Briefing, Clinical Delivery, February 2017: 
https://www.york.ac.uk/media/satsu/members-area-internal/regenablemedmembersarea/
RM%20Policy%20Briefing%20Clinical%20delivery%20_final.pdf  
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Thank you for your attention! 
 
Contact:  aurelie.mahalatchimy@gmail.com 
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